

REMARKS

Claim 62 is currently pending and under consideration. New claims 63-97 have been added in an effort to focus the application upon certain lead groups of compounds that possess a commonality of features.

Support for new claims 63-97 can be found in the specification. In particular, support for claim 63 can be found, for example, in claim 62, in the embodiment identified on page 226, lines 31-33, and in all of the compounds identified at pages 227 to 257 that fit within claim 62. Support for claim 64 can be found, for example, in claim 62, and in eighty-two of the compounds identified at pages 227 to 257 which possess a single covalent bond for A, a hydrido for X^0 , and hydrido or halo (chloro) substituents for R^1 . Support for claim 65 can be found, for example, in claim 62 and in sixty-eight of the compounds identified at pages 227 to 257 which possess a number of different C2-C8 alkyl groups for B. Support for claim 66 can be found, for example, in claim 62 and in thirty of the compounds identified at pages 227 to 257 which possess a number of compounds in which Q is unsubstituted, monosubstituted or disubstituted phenyl.¹ Support for claim 67 can be found, for example, in claim 62 and in seventy-two of the compounds identified at pages 227 to 257 which possess a number of compounds in which Q is unsubstituted, monosubstituted or disubstituted phenyl. In particular, support for disubstituted phenyl moieties for Q can be found in the thirteen compounds identified at pages 253, line 5 through page 254, line 5. Support for claim 68 can be found, for example, in claim 62 and in Example 29. Support for claim 69 can be found, for example, in claim 62, at page 254, lines 4-5 and in the Declaration of Michael S. South (the "Declaration") discussed below. Support for claims 70-81 can be found in the compounds disclosed at pages 253, line 5 through page 254, line 5. Support for claims 82-90 can be found, for example, in claim 62 and in many of the compounds disclosed at pages 232-234. Finally, support for claims 91-97 can be found, for example, in claim 62 and in the compounds disclosed at pages 238, line 3 through page 239, line 7.

Further support for claims 63-69 can be found in the Declaration, attached hereto. The Declaration provides the data for compound 29 and compound 30, both of

¹R² is generally defined as Z⁰-Q. Thus, when Z⁰ is a single covalent bond, R² is Q. Accordingly, in claim 62 and in the new claims submitted with this Supplementary Amendment, the variable Q is used.

which were previously disclosed in the application.² These compounds are embraced by new claims 63-67. Both compounds 29 and 30 possess an alkyl group for B, a single covalent bond for A, hydrido for R¹, a disubstituted phenyl for Q and a benzamidine moiety for Y⁰. Further, as detailed in the Declaration, the compounds exhibit the advantage of selectivity for human tissue factor VIIa over both human thrombin and human factor Xa.

²Compound 29 was disclosed in Example 29 on pages 222-224 and Compound 30 was disclosed on page 254, lines 4 and 5.

CONCLUSION

In light of the foregoing, Applicants respectfully request entry of the new claims and solicit an allowance of all pending claims. The Examiner is invited to contact the undersigned attorney should any issue arise.

The Commissioner is hereby authorized to charge any fee deficiency in connection with this amendment to Deposit Account Number 19-1345 in the name of Senniger, Powers, Leavitt & Roedel.

Respectfully submitted,

A handwritten signature in black ink, appearing to be 'EJH', with a horizontal line extending to the right.

Edward J. Hejlek, Reg. No. 31,525
SENNIGER, POWERS, LEAVITT & ROEDEL
One Metropolitan Square, 16th Floor
St. Louis, Missouri 63102
(314) 231-5400

EJH/BSS/dmt

Express Mail Label No. EL 890688123 US